Allergan Ltd and Cephalon (UK) Limited have each infringed the ABPI code of conduct for the pharmaceutical industry. To highlight these violations, both of which are the subject of pharmaceutical advertising in the press, doctors and nurses.
Allergan-if AUTH/2335/7/10
For non-fulfilment of a commitment not to use the data in a way that previously had been ruled in violation of the code, Allergan was ruled in violation of the provisions of the following code:
Clause 2-bringing discredit on and reducing confidence in the pharmaceutical industry.
Clause 9. 1. failing to maintain a high level. Clause 25-non-compliance with an undertaking.
Allergan-if AUTH/2346/8/10
For non-fulfilment of a commitment not to use the data in a way that previously had been ruled in violation of the code, Allergan was ruled in violation of the provisions of the following code:
Clause 2-bringing discredit on and reducing confidence in the pharmaceutical industry.
Clause 9. 1. failing to maintain a high level.
Clause 25-non-compliance with an undertaking.
Cephalon-if AUTH/2361/10/10
Inadequate to provide hospitality to delegates had sponsored to participate in a European Conference, Cephalon was ruled in violation of the provisions of the following code:
Clause 2-bringing discredit on the pharmaceutical industry.
Clause 1. 7-failure to comply with all applicable codes.
Clause 9. 1. failing to maintain a high level.
Clause 15.2-representatives failing to maintain a high standard of ethical conduct.
15.9-distribution clause briefing material which advocated a course of action likely to violate the code.
Clause 19.1-offering hospitality.
According to provisions in its Constitution and proceedings, the prescription drugs code of practice Authority (PMCPA) advertises brief details of all cases where companies are governed in violation of clause 2 of the code, are obliged to issue a statement corrective or are the subject of a public rebuke.
Your ads will appear in The Nursing Standard on 24 March 2011 and theBMJ and The pharmaceutical Journal on March 26, 2011.
The full case reports were published in February PMCPA Review and code of practice are also available here.
Source:
The code of prescription medications practice authority
Note: all medical information published on this website are not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional. For more information, please read our terms and conditions.
Please note that we publish your name, but we do not publish your email. Is used only to let you know when your message is posted. We do not use it for other purposes. Please see our privacy policy for more information.
If you write about specific drugs or operations not for healthcare professionals to name names.
All opinions are moderate before being included (to stop spam)
Contact our editorial News
For corrections of factual information or to contact the Editorial Department, please use our feedback form.
Please send any medical news or press releases for: health news
Privacy policy | Terms and conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd c 2004-2010 all rights reserved.
沒有留言:
張貼留言